Previous 10 | Next 10 |
BAUDETTE, Minn. , May 9, 2019 /PRNewswire/ -- For the first quarter 2019: Net revenues of $52.9 million , an increase of 14% versus 2018 GAAP net income of $0.4 million and diluted GAAP earnings per share of $0.04 Record adjusted non-GAAP EBITDA of $22.3 million ...
BAUDETTE, Minn. , May 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2019 financial results on Thursday, May 9, 2019 , before the opening of the U.S. financial markets. The earnings press release will b...
BAUDETTE, Minn. , April 15, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that it has entered into a Distribution Agreement with a U.S. based injectable manufacturer to commercialize a unique specialty injectable product. ...
Private equity shops Apollo Global Management and CVC Capital Partners are apparently bidding for Perrigo's ( PRGO +2.6% ) generic pharmaceuticals unit according to informed sources who add that the business could fetch more than $2.5B. More news on: Perrigo Company plc, Akorn, In...
ANI Pharmaceuticals ( ANIP -1.2% ) has launched 18mg and 27mg Methylphenidate Hydrochloride Extended-Release Tablets, indicated as a treatment for Attention Deficit Hyperactivity Disorder ("ADHD"). More news on: ANI Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
BAUDETTE, Minn. , March 27, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced the launch of 18mg and 27mg Methylphenidate Hydrochloride Extended-Release Tablets, indicated as a treatment for Attention Deficit Hyperactivity Disorder...
ANI Pharmaceuticals Inc (ANIP) Q4 2018 Earnings Conference Call February 27, 2019 10:30 AM ET Company Participants Arthur Przybyl - President and Chief Executive Officer Stephen Carey - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymond James Dewey...
ANI Pharmaceuticals ( ANIP ) Q4 results : Revenues: $57.1M (+20.7%). More news on: ANI Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
ANI Pharmaceuticals (NASDAQ: ANIP ): Q4 Non-GAAP EPS of $1.32 beats by $0.08 ; GAAP EPS of $0.46 beats by $0.02 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BAUDETTE, Minn. , Feb. 27, 2019 /PRNewswire/ -- For the full year ended December 31, 2018 : Record net revenues of $201.6 million , an increase of 14% versus 2017 GAAP net income of $15.5 million and diluted GAAP earnings per share of $1.30 Adjusted non-GAAP EBITDA ...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2024 financial results on Tuesday, August 6, 2024, prior to the market open. Nikh...
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...